Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Impact of risperidone on the use of mental health care resources.

Viale G, Mechling L, Maislin G, Durkin M, Engelhart L, Lawrence BJ.

Psychiatr Serv. 1997 Sep;48(9):1153-9.

PMID:
9285975
2.

Effects of risperidone therapy on the use of mental health care resources in Salt Lake County, Utah.

Carter C, Stevens M, Durkin M.

Clin Ther. 1998 Mar-Apr;20(2):352-63.

PMID:
9589826
3.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
4.

Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.

Mladsi DM, Grogg AL, Irish WD, Lopez RB, Degen K, Swann A, Nimsch CT.

Curr Med Res Opin. 2004 Dec;20(12):1883-93.

PMID:
15701206
5.

Impact of risperidone long acting injection on resource utilization in psychiatric secondary care.

Taylor M, Currie A, Lloyd K, Price M, Peperell K.

J Psychopharmacol. 2008 Mar;22(2):128-31. doi: 10.1177/0269881107084068. Epub 2008 Feb 28.

PMID:
18308820
6.

Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.

Taylor DM, Wright T, Libretto SE; Risperidone Olanzapine Drug Outcomes Studies in Schizophrenia (RODOS) U.K. Investigator Group.

J Clin Psychiatry. 2003 May;64(5):589-97.

PMID:
12755664
7.

Risperidone compared with olanzapine in a naturalistic clinical study in Ireland: a cost analysis.

Lucey JV, Libretto SE.

Ir J Med Sci. 2003 Oct-Dec;172(4):195-201.

PMID:
15029989
8.

Use of healthcare services by patients treated with risperidone versus conventional antipsychotic agents.

Gianfrancesco F, Durkin MB, Mahmoud R, Wang RH.

Pharmacoeconomics. 2002;20(6):413-27.

PMID:
12052100
9.

Cost analysis of risperidone long-acting injection in the treatment of schizophrenia and schizoaffective disorders in Hong Kong: an approach using generalised estimating equations.

Wu DB, Lee EH, Chung WS, Chow DP, Lee VW, Wong MC, Lee KK.

Psychiatry Res. 2013 Dec 30;210(3):745-50. doi: 10.1016/j.psychres.2013.07.012. Epub 2013 Sep 3.

PMID:
24012164
10.
11.

The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden.

Willis M, Svensson M, Löthgren M, Eriksson B, Berntsson A, Persson U.

Eur J Health Econ. 2010 Dec;11(6):585-94. doi: 10.1007/s10198-009-0215-9. Epub 2010 Jan 19.

PMID:
20084535
12.

Resource utilization in a Canadian national study of people with schizophrenia and related psychotic disorders.

Kopala L, Smith G, Malla A, Williams R, Love L, Talling D, Balshaw R.

Acta Psychiatr Scand Suppl. 2006;(430):29-39.

PMID:
16542323
13.

Association of co-morbidities with prescribing patterns and cost savings: olanzapine versus risperidone for schizophrenia.

Yu W, Ren XS, Lee AF, Herz L, Huang YH, Kazis LE.

Pharmacoeconomics. 2006;24(12):1233-48.

PMID:
17129077
14.

Patient characteristics and the likelihood of initiation on olanzapine or risperidone among patients with schizophrenia.

Ren XS, Kazis LE, Lee AF, Huang YH, Hamed A, Cunningham F, Herz L, Miller DR.

Schizophr Res. 2005 Sep 15;77(2-3):167-77.

PMID:
15894460
15.

The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.

Gibson PJ, Damler R, Jackson EA, Wilder T, Ramsey JL.

Value Health. 2004 Jan-Feb;7(1):22-35.

16.
17.

Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia.

Barnett PG, Scott JY, Krystal JH, Rosenheck RA; CSP 555 Research Group.

J Clin Psychiatry. 2012 May;73(5):696-702. doi: 10.4088/JCP.11m07070.

PMID:
22697193
19.

Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration.

Ren XS, Crivera C, Sikirica M, Dirani R, Qian S, Kazis LE.

J Clin Pharm Ther. 2011 Jun;36(3):383-9. doi: 10.1111/j.1365-2710.2010.01211.x. Epub 2010 Nov 10.

PMID:
21062329
20.

Cost evaluation of risperidone compared with olanzapine.

Byerly MJ, Weber M, Brooks D, Casey SB, Elliot S, Hawkins J.

Psychiatr Serv. 2003 May;54(5):742-4.

PMID:
12719509
Items per page

Supplemental Content

Write to the Help Desk